重要性： “精神药物”涉及到大脑和身体的许多地方，影响广泛。因此，许多这些药物可以被重新用于具有高公共卫生影响的非精神疾病。观察：基于随机对照试验（RCTs），选择性血清素再摄取抑制剂（SSRI）氟伏沙明被证明对COVID-19治疗有效，其他抗抑郁药物的效益也得出了结论，该结论基于观察和临床前研究。在本篇综述中，我们阐明了SSRI和其他精神药物的特点，使它们成为用于非精神疾病的候选药物。我们总结了导致氟伏沙明用于COVID-19的研究，并提供如何安全使用的指导。我们总结了针对COVID-19和长期COVID的其他抗抑郁药物的有益研究。我们还描述了精神药物在治疗长期COVID，阿尔茨海默病，癌症和其他疾病方面的假定机制。结论和相关性：精神药物重新用途具有潜在的临床和公共卫生影响。针对这种再用途的挑战存在，但对于研究人员，监管机构和资助方，存在解决方案以克服这些挑战。©版权所有2023年医师研究生出版社。

Importance: "Psychotropic" drugs have widespread reach and impact throughout the brain and body. Thus, many of these drugs could be repurposed for non-psychiatric indications of high public health impact. Observations: The selective serotonin reuptake inhibitor (SSRI) fluvoxamine was shown efficacious as a COVID-19 treatment based on randomized controlled trials (RCTs), and a benefit of other antidepressants has been posited based on observational and preclinical studies. In this review, we illuminate features of SSRIs and other psychiatric drugs that make them candidates to repurpose for non-psychiatric indications. We summarize research that led to fluvoxamine's use in COVID-19 and provide guidance on how to use it safely. We summarize studies suggestive of benefit of other antidepressants versus COVID-19 and long COVID. We also describe putative mechanisms of psychiatric drugs in treating long COVID, Alzheimer's disease, cancer, and other conditions. Conclusion and Relevance: There is a potentially great clinical and public health impact of psychotropic drug repurposing. Challenges exist to such repurposing efforts, but solutions exist for researchers, regulators, and funders that overcome these challenges.© Copyright 2023 Physicians Postgraduate Press, Inc.